Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 391

1.

Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study.

Westerberg M, Franck Lissbrant I, Damber JE, Robinson D, Garmo H, Stattin P.

Acta Oncol. 2019 Sep 17:1-6. doi: 10.1080/0284186X.2019.1662084. [Epub ahead of print]

PMID:
31526166
2.

Single institution followed by national implementation of systematic surgical quality control and feedback for radical prostatectomy: a 20-year journey.

Stranne J, Axen E, Franck-Lissbrant I, Fransson P, Frånlund M, Hugosson J, Khatami A, Koss-Modig K, Lodding P, Nyberg M, Stattin P, Bratt O.

World J Urol. 2019 Aug 6. doi: 10.1007/s00345-019-02887-4. [Epub ahead of print]

PMID:
31388817
3.

Population-based, nationwide registration of prostatectomies in Sweden.

Cazzaniga W, Godtman RA, Carlsson S, Ahlgren G, Johansson E, Robinson D, Hugosson J, Stattin P.

J Surg Oncol. 2019 Sep;120(4):803-812. doi: 10.1002/jso.25643. Epub 2019 Jul 29.

PMID:
31355454
4.

Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study.

Beckmann K, Russell B, Josephs D, Garmo H, Haggstrom C, Holmberg L, Stattin P, Van Hemelrijck M, Adolfsson J.

BMC Cancer. 2019 Jun 21;19(1):612. doi: 10.1186/s12885-019-5846-3.

5.

Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor.

Thysell E, Vidman L, Ylitalo EB, Jernberg E, Crnalic S, Iglesias-Gato D, Flores-Morales A, Stattin P, Egevad L, Widmark A, Rydén P, Bergh A, Wikström P.

Mol Oncol. 2019 Aug;13(8):1763-1777. doi: 10.1002/1878-0261.12526. Epub 2019 Jun 27.

6.

How to measure temporal changes in care pathways for chronic diseases using health care registry data.

Ventimiglia E, Van Hemelrijck M, Lindhagen L, Stattin P, Garmo H.

BMC Med Inform Decis Mak. 2019 May 30;19(1):103. doi: 10.1186/s12911-019-0823-y.

7.

Epidemiology of hydrocele and spermatocele; incidence, treatment and complications.

Lundström KJ, Söderström L, Jernow H, Stattin P, Nordin P.

Scand J Urol. 2019 Apr - Jun;53(2-3):134-138. doi: 10.1080/21681805.2019.1600582. Epub 2019 Apr 16.

PMID:
30990342
8.

Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome.

Hammarsten P, Josefsson A, Thysell E, Lundholm M, Hägglöf C, Iglesias-Gato D, Flores-Morales A, Stattin P, Egevad L, Granfors T, Wikström P, Bergh A.

Mod Pathol. 2019 Sep;32(9):1310-1319. doi: 10.1038/s41379-019-0260-6. Epub 2019 Apr 12.

PMID:
30980038
9.

Mini Review on the Use of Clinical Cancer Registers for Prostate Cancer: The National Prostate Cancer Register (NPCR) of Sweden.

Cazzaniga W, Ventimiglia E, Alfano M, Robinson D, Lissbrant IF, Carlsson S, Styrke J, Montorsi F, Salonia A, Stattin P.

Front Med (Lausanne). 2019 Mar 22;6:51. doi: 10.3389/fmed.2019.00051. eCollection 2019. Review.

10.

The triglyceride-glucose index as a measure of insulin resistance and risk of obesity-related cancers.

Fritz J, Bjørge T, Nagel G, Manjer J, Engeland A, Häggström C, Concin H, Teleka S, Tretli S, Gylling B, Lang A, Stattin P, Stocks T, Ulmer H.

Int J Epidemiol. 2019 Mar 3. pii: dyz053. doi: 10.1093/ije/dyz053. [Epub ahead of print]

PMID:
30945727
11.

The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS).

Bratt O, Holmberg E, Andrén O, Carlsson S, Drevin L, Johansson E, Josefsson A, Nyberg M, Sandberg J, Stattin P, Robinsson D.

Eur Urol. 2019 Oct;76(4):461-466. doi: 10.1016/j.eururo.2019.02.035. Epub 2019 Mar 14.

PMID:
30878303
12.

The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies.

Watts EL, Perez-Cornago A, Appleby PN, Albanes D, Ardanaz E, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chubb SAP, Cook MB, Deschasaux M, Donovan JL, English DR, Flicker L, Freedman ND, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Häggström C, Haiman C, Hamdy FC, Hercberg S, Holly JM, Huang J, Huang WY, Johansson M, Kaaks R, Kubo T, Lane JA, Layne TM, Le Marchand L, Martin RM, Metter EJ, Mikami K, Milne RL, Morris HA, Mucci LA, Neal DE, Neuhouser ML, Oliver SE, Overvad K, Ozasa K, Pala V, Pernar CH, Pollak M, Rowlands MA, Schaefer CA, Schenk JM, Stattin P, Tamakoshi A, Thysell E, Touvier M, Trichopoulou A, Tsilidis KK, Van Den Eeden SK, Weinstein SJ, Wilkens L, Yeap BB, Key TJ, Allen NE, Travis RC.

Int J Cancer. 2019 Mar 15. doi: 10.1002/ijc.32276. [Epub ahead of print]

PMID:
30873591
13.

Linear age-course effects on the associations between body mass index, triglycerides, and female breast and male liver cancer risk: An internal replication study of 800,000 individuals.

Häggström C, Jonsson H, Bjørge T, Nagel G, Manjer J, Ulmer H, Drake I, Ghaderi S, Lang A, Engeland A, Stattin P, Stocks T.

Int J Cancer. 2019 Feb 27. doi: 10.1002/ijc.32240. [Epub ahead of print]

PMID:
30815851
14.

Androgen deprivation therapy for prostate cancer and risk of dementia.

Robinson D, Garmo H, Van Hemelrijck M, Damber JE, Bratt O, Holmberg L, Wahlund LO, Stattin P, Adolfsson J.

BJU Int. 2019 Jul;124(1):87-92. doi: 10.1111/bju.14666. Epub 2019 Feb 6.

PMID:
30637900
15.

Prostate cancer induces C/EBPβ expression in surrounding epithelial cells which relates to tumor aggressiveness and patient outcome.

Adamo H, Hammarsten P, Hägglöf C, Dahl Scherdin T, Egevad L, Stattin P, Halin Bergström S, Bergh A.

Prostate. 2019 Apr;79(5):435-445. doi: 10.1002/pros.23749. Epub 2018 Dec 11.

PMID:
30536410
16.

Anastomotic leakage after anterior resection in patients with rectal cancer previously irradiated for prostate cancer.

Sverrisson I, Folkvaljon F, Chabok A, Stattin P, Smedh K, Nikberg M.

Eur J Surg Oncol. 2019 Mar;45(3):341-346. doi: 10.1016/j.ejso.2018.11.015. Epub 2018 Nov 20.

17.

Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.

Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P, Van Hemelrijck M.

Eur Urol. 2019 Apr;75(4):676-683. doi: 10.1016/j.eururo.2018.11.022. Epub 2018 Nov 26.

PMID:
30497883
18.

Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study.

Arthur R, Møller H, Garmo H, Häggström C, Holmberg L, Stattin P, Malmström H, Lambe M, Hammar N, Walldius G, Robinson D, Jungner I, Van Hemelrijck M.

Cancer Causes Control. 2019 Feb;30(2):195-206. doi: 10.1007/s10552-018-1093-1. Epub 2018 Nov 12.

PMID:
30421156
19.

Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study.

Thomsen FB, Bosco C, Garmo H, Adolfsson J, Hammar N, Stattin P, Van Hemelrijck M.

Acta Oncol. 2019 Jan;58(1):110-118. doi: 10.1080/0284186X.2018.1529427. Epub 2018 Oct 30.

PMID:
30375907
20.

Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden.

Nugin H, Folkvaljon Y, Damber JE, Adolfsson J, Robinson D, Stattin P.

Scand J Urol. 2018 Aug;52(4):277-284. doi: 10.1080/21681805.2018.1512650. Epub 2018 Oct 26.

PMID:
30362868
21.

Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.

Li W, Middha M, Bicak M, Sjoberg DD, Vertosick E, Dahlin A, Häggström C, Hallmans G, Rönn AC, Stattin P, Melander O, Ulmert D, Lilja H, Klein RJ.

Eur Urol. 2018 Dec;74(6):710-719. doi: 10.1016/j.eururo.2018.06.021. Epub 2018 Jul 7.

PMID:
30289108
22.

Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study.

Cazzaniga W, Garmo H, Robinson D, Holmberg L, Bill-Axelson A, Stattin P.

BJU Int. 2019 Mar;123(3):421-428. doi: 10.1111/bju.14563. Epub 2018 Oct 25.

PMID:
30253031
23.

Defining Intermediate Risk Prostate Cancer Suitable for Active Surveillance.

Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P.

J Urol. 2019 Feb;201(2):292-299. doi: 10.1016/j.juro.2018.09.042.

PMID:
30240688
24.

Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies.

Watts EL, Appleby PN, Perez-Cornago A, Bueno-de-Mesquita HB, Chan JM, Chen C, Cohn BA, Cook MB, Flicker L, Freedman ND, Giles GG, Giovannucci E, Gislefoss RE, Hankey GJ, Kaaks R, Knekt P, Kolonel LN, Kubo T, Le Marchand L, Luben RN, Luostarinen T, Männistö S, Metter EJ, Mikami K, Milne RL, Ozasa K, Platz EA, Quirós JR, Rissanen H, Sawada N, Stampfer M, Stanczyk FZ, Stattin P, Tamakoshi A, Tangen CM, Thompson IM, Tsilidis KK, Tsugane S, Ursin G, Vatten L, Weiss NS, Yeap BB, Allen NE, Key TJ, Travis RC.

Eur Urol. 2018 Nov;74(5):585-594. doi: 10.1016/j.eururo.2018.07.024. Epub 2018 Aug 1.

25.

Reply to the letter to the editor 'Age at diagnosis and prognosis among prostate cancer patients treated with radiotherapy: evidenced from three independent cohort studies' by X. Dong, G. Ma and F. Chen.

Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P.

Ann Oncol. 2018 Sep 1;29(9):2020-2021. doi: 10.1093/annonc/mdy236. No abstract available.

PMID:
29992285
26.

Circulating isoflavone and lignan concentrations and prostate cancer risk: a meta-analysis of individual participant data from seven prospective studies including 2,828 cases and 5,593 controls.

Perez-Cornago A, Appleby PN, Boeing H, Gil L, Kyrø C, Ricceri F, Murphy N, Trichopoulou A, Tsilidis KK, Khaw KT, Luben RN, Gislefoss RE, Langseth H, Drake I, Sonestedt E, Wallström P, Stattin P, Johansson A, Landberg R, Nilsson LM, Ozasa K, Tamakoshi A, Mikami K, Kubo T, Sawada N, Tsugane S, Key TJ, Allen NE, Travis RC.

Int J Cancer. 2018 Dec 1;143(11):2677-2686. doi: 10.1002/ijc.31640. Epub 2018 Sep 29.

27.

Longitudinal study of body mass index, dyslipidemia, hyperglycemia, and hypertension in 60,000 men and women in Sweden and Austria.

Van Hemelrijck M, Ulmer H, Nagel G, Peter RS, Fritz J, Myte R, van Guelpen B, Föger B, Concin H, Häggström C, Stattin P, Stocks T.

PLoS One. 2018 Jun 13;13(6):e0197830. doi: 10.1371/journal.pone.0197830. eCollection 2018.

28.

Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: A prospective pooled cohort study of 800,000 men and women.

Teleka S, Häggström C, Nagel G, Bjørge T, Manjer J, Ulmer H, Liedberg F, Ghaderi S, Lang A, Jonsson H, Jahnson S, Orho-Melander M, Tretli S, Stattin P, Stocks T.

Int J Cancer. 2018 Dec 15;143(12):3071-3082. doi: 10.1002/ijc.31597. Epub 2018 Oct 16.

PMID:
29756343
29.

Editorial Comment.

Stattin P.

J Urol. 2018 Aug;200(2):325-326. doi: 10.1016/j.juro.2018.02.3119. Epub 2018 May 8. No abstract available.

PMID:
29746843
30.

Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and Type 2 diabetes mellitus.

Häggström C, Van Hemelrijck M, Garmo H, Robinson D, Stattin P, Rowley M, Coolen ACC, Holmberg L.

Int J Cancer. 2018 Oct 15;143(8):1868-1875. doi: 10.1002/ijc.31587. Epub 2018 Aug 10.

31.

Concordance of Non-Low-Risk Disease Among Pairs of Brothers With Prostate Cancer.

Jansson F, Drevin L, Frisell T, Stattin P, Bratt O, Akre O.

J Clin Oncol. 2018 Jun 20;36(18):1847-1852. doi: 10.1200/JCO.2017.76.6907. Epub 2018 Apr 13.

PMID:
29652556
32.

A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0.

Russell B, Garmo H, Beckmann K, Stattin P, Adolfsson J, Van Hemelrijck M.

PLoS One. 2018 Apr 12;13(4):e0195690. doi: 10.1371/journal.pone.0195690. eCollection 2018.

33.

Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review.

Kinsella N, Stattin P, Cahill D, Brown C, Bill-Axelson A, Bratt O, Carlsson S, Van Hemelrijck M.

Eur Urol. 2018 Sep;74(3):261-280. doi: 10.1016/j.eururo.2018.02.026. Epub 2018 Mar 26.

34.

Public online reporting from a nationwide population-based clinical prostate cancer register.

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

BJU Int. 2018 Jul;122(1):8-10. doi: 10.1111/bju.14213. Epub 2018 Apr 17. No abstract available.

35.

Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study.

Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Armes J, Holmberg L, Adolfsson J, Van Hemelrijck M.

BMJ Open. 2018 Mar 16;8(3):e020787. doi: 10.1136/bmjopen-2017-020787.

36.

The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study.

Gnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P, Lophatananon A.

BMC Med. 2018 Feb 28;16(1):31. doi: 10.1186/s12916-018-1019-5.

37.

A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus.

Crawley D, Chamberlain F, Garmo H, Rudman S, Zethelius B, Holmberg L, Adolfsson J, Stattin P, Carroll P, Van Hemelrijck M.

Ecancermedicalscience. 2018 Jan 25;12:802. doi: 10.3332/ecancer.2018.802. eCollection 2018. Review.

38.

Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden.

Franck Lissbrant I, Ventimiglia E, Robinson D, Törnblom M, Hjälm-Eriksson M, Lambe M, Folkvaljon Y, Stattin P.

Scand J Urol. 2018 Apr;52(2):143-150. doi: 10.1080/21681805.2018.1426039. Epub 2018 Feb 1.

PMID:
29385878
39.

Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study.

Tomic K, Ventimiglia E, Robinson D, Häggström C, Lambe M, Stattin P.

Int J Cancer. 2018 Jun 15;142(12):2478-2484. doi: 10.1002/ijc.31272. Epub 2018 Feb 2.

40.

Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study.

Arthur R, Williams R, Garmo H, Holmberg L, Stattin P, Malmström H, Lambe M, Hammar N, Walldius G, Robinsson D, Jungner I, Van Hemelrijck M.

Int J Cancer. 2018 Jun 1;142(11):2254-2262. doi: 10.1002/ijc.31256. Epub 2018 Jan 26.

41.

Diagnosspecifika översikter är viktiga vertyg för cancervården.

Stattin P, Franck Lissbrant I.

Lakartidningen. 2018 Jan 9;115. pii: EYFW. Swedish. No abstract available.

PMID:
29319829
Free Article
42.

Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases.

FitzGerald LM, Zhao S, Leonardson A, Geybels MS, Kolb S, Lin DW, Wright JL, Eeles R, Kote-Jarai Z, Govindasami K, Giles GG, Southey MC, Schleutker J, Tammela TL, Sipeky C, Penney KL, Stampfer MJ, Gronberg H, Wiklund F, Stattin P, Hugosson J, Karyadi DM, Ostrander EA, Feng Z, Stanford JL.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):228-237. doi: 10.1038/s41391-017-0029-2. Epub 2018 Jan 3.

43.

Circulating sex hormones in relation to anthropometric, sociodemographic and behavioural factors in an international dataset of 12,300 men.

Watts EL, Appleby PN, Albanes D, Black A, Chan JM, Chen C, Cirillo PM, Cohn BA, Cook MB, Donovan JL, Ferrucci L, Garland CF, Giles GG, Goodman PJ, Habel LA, Haiman CA, Holly JMP, Hoover RN, Kaaks R, Knekt P, Kolonel LN, Kubo T, Le Marchand L, Luostarinen T, MacInnis RJ, Mäenpää HO, Männistö S, Metter EJ, Milne RL, Nomura AMY, Oliver SE, Parsons JK, Peeters PH, Platz EA, Riboli E, Ricceri F, Rinaldi S, Rissanen H, Sawada N, Schaefer CA, Schenk JM, Stanczyk FZ, Stampfer M, Stattin P, Stenman UH, Tjønneland A, Trichopoulou A, Thompson IM, Tsugane S, Vatten L, Whittemore AS, Ziegler RG, Allen NE, Key TJ, Travis RC.

PLoS One. 2017 Dec 27;12(12):e0187741. doi: 10.1371/journal.pone.0187741. eCollection 2017.

44.

Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study.

Robinson D, Garmo H, Lissbrant IF, Widmark A, Pettersson A, Gunnlaugsson A, Adolfsson J, Bratt O, Nilsson P, Stattin P.

Eur Urol. 2018 Apr;73(4):502-511. doi: 10.1016/j.eururo.2017.11.039. Epub 2017 Dec 15.

45.

The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data.

Lycken M, Drevin L, Garmo H, Stattin P, Adolfsson J, Lissbrant IF, Holmberg L, Bill-Axelson A.

Eur J Cancer. 2018 Jan;88:101-108. doi: 10.1016/j.ejca.2017.10.023. Epub 2017 Dec 6.

PMID:
29216521
46.

Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study.

Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P.

Ann Oncol. 2018 Feb 1;29(2):377-385. doi: 10.1093/annonc/mdx742.

PMID:
29161337
47.

Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma.

Loeb S, Ventimiglia E, Salonia A, Folkvaljon Y, Stattin P.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx086.

48.

Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.

Assel M, Dahlin A, Ulmert D, Bergh A, Stattin P, Lilja H, Vickers AJ.

Eur Urol. 2018 Jun;73(6):961-967. doi: 10.1016/j.eururo.2017.10.004. Epub 2017 Oct 21.

49.

Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study.

Kristiansen A, Drevin L, Delahunt B, Samaratunga H, Robinson D, Franck Lissbrant I, Stattin P, Egevad L.

Pathology. 2017 Dec;49(7):715-720. doi: 10.1016/j.pathol.2017.08.008. Epub 2017 Oct 14.

PMID:
29037803
50.

Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.

Bosco C, Wong C, Garmo H, Crawley D, Holmberg L, Hammar N, Adolfsson J, Stattin P, Van Hemelrijck M.

BJU Int. 2018 Feb;121(2):260-267. doi: 10.1111/bju.14023. Epub 2017 Oct 17.

Supplemental Content

Loading ...
Support Center